With 2025 marking the UN High-level meeting on Non-Communicable Diseases, there is a clear need for effective policies and regulatory frameworks; recognising chronic liver disease, especially due to MASLD/MASH, as one of the major non-communicable diseases would be a great starting point! This webinar offers valuable insights into the current and future priorities of liver health policy and regulation.

Key Topics: 

• Strategic pathways for MASLD/MASH to be included in global policy discussions
• Accelerating access to new treatments, reimbursements, and approvals
• The crucial role of payors in enabling early screening and linkage to care
• Navigating the complex regulatory landscape of drug and diagnostic approvals

Who should watch?

Clinicians involved in hepatology; health policy experts, regulatory experts, academics and researchers, industry,  patient associations, patient advocates, primary healthcare professionals, gastroenterologists, hepatologists, and anyone interested in learning more about chronic liver disease from a policy perspective.

Moderators: 

1. Veronica Miller, PhD, Adjunct Professor IDV, Berkeley School of Public Health / Director, Forum for Collaborative Research, USA
2. Jeffrey V. Lazarus, Professor, CUNY Graduate School of Public Health and Health Policy, NY, USA and the Barcelona Institute for Global Health (ISGlobal), Spain / Director, Global Think-tank on Steatotic Liver Disease

Panelists: 

1. Keri Hildick, Chief Strategy Officer, Perspectum, UK
2. Gail Hinkson, CEO, Summit Clinical Research, LLC, USA
3. Morten Karsdal, CEO, Nordic Bioscience, Denmark
4. Luis Antonio Diaz Piga, Hepatologist/Researcher, MASLD Research Center, University of California San Diego, USA